HepatoBurn

The label — what’s actually in the HepatoBurn capsule

HepatoBurn’s central pitch is that a compromised liver is the hidden bottleneck in your weight-loss efforts, and that its five-ingredient formula repairs that bottleneck. The mechanism is not invented from whole cloth — NAFLD and hepatic insulin resistance are genuinely associated with metabolic dysfunction. The question is whether this product delivers the right compounds at the right doses to do anything measurable about it.

Per the Supplement Facts panel pulled from a product bottle purchased April 2026:

Ingredient	Dose disclosed	Claimed function on label
Proprietary blend	total undisclosed	—
└ Silymarin (from milk thistle extract, standardized)	undisclosed	Liver protection, enzyme normalization
└ Berberine HCl	undisclosed	Glycemic support, AMPK activation
└ Choline (as choline bitartrate)	undisclosed	Hepatic fat transport, methyl donor
└ Molybdenum (as molybdenum glycinate)	undisclosed	Detoxification enzyme cofactor
└ Glutathione (as reduced L-glutathione)	undisclosed	Antioxidant, liver cell protection

None of the five active ingredients has a disclosed individual dose. The total blend weight is not printed on the label. This is the structural flaw that defines this product’s rating. Berberine in particular has a well-characterized therapeutic dose range — 1,000–1,500 mg/day in the majority of positive trials — below which its glycemic effects are negligible. Whether HepatoBurn sits above or below that threshold is the formulator’s private information.

Ingredient-by-ingredient evidence review

Berberine HCl

Berberine is the most clinically interesting ingredient in this formulation and the reason it earns a Cautious rather than an outright Skeptical rating. It activates AMP-activated protein kinase (AMPK), a cellular energy sensor that functions similarly to the mechanism targeted by metformin, and has been studied extensively in the past two decades.

A 2012 RCT by Yan et al. (Evidence-Based Complementary and Alternative Medicine) randomized 48 overweight subjects to 1,500 mg/day berberine or placebo over 12 weeks and found statistically significant reductions in BMI, waist circumference, triglycerides, and fasting glucose. A 2020 meta-analysis by Rondanelli et al. (Nature Reviews Endocrinology) analyzed 49 RCTs and found consistent improvements in HbA1c, fasting glucose, LDL cholesterol, and triglycerides at 1,000–1,500 mg/day. The effect sizes are clinically meaningful — comparable to low-dose metformin in some head-to-head comparisons.

The dose-response relationship is not forgiving. Studies using 500 mg/day or below show marginal, often non-significant effects. The 1,500 mg/day target is the clinically supported threshold in the majority of positive published trials. HepatoBurn’s proprietary blend leaves you unable to verify which range you’re in. If the formulation uses 300–500 mg berberine to manage cost and capsule fill weight, you are almost certainly below the therapeutic threshold.

Silymarin (milk thistle extract)

Silymarin is the flavonoid complex extracted from Silybum marianum. Its hepatoprotective mechanisms are well-characterized: antioxidant activity, inhibition of lipid peroxidation, anti-inflammatory cytokine modulation, and antifibrotic effects on hepatic stellate cells.

Human trial data is substantial by supplement standards. A 2017 systematic review by Gillessen and Schmidt (Hepatology International) covering 19 RCTs in patients with chronic liver disease found consistent reductions in ALT and AST at doses of 280–560 mg standardized silymarin daily. A meta-analysis by Zhong et al. (2017, PLOS ONE) covering NAFLD specifically found statistically significant liver enzyme improvements at similar dose ranges.

What silymarin does not have is a direct RCT linking liver enzyme normalization to subsequent clinically meaningful weight loss in metabolically healthy people. The mechanistic chain from silymarin → improved liver function → fat loss is biologically plausible but is not established in human trial data. HepatoBurn’s marketing presents this chain as settled; the evidence presents it as theoretical.

Choline (as choline bitartrate)

Choline is an essential nutrient involved in hepatic fat transport via very-low-density lipoprotein (VLDL) secretion. Choline deficiency is a recognized cause of non-alcoholic steatohepatitis in animal models and is associated with NAFLD progression in human observational data. The Institute of Medicine established an Adequate Intake of 425–550 mg choline daily for adults.

This is a legitimate ingredient for a liver-support formulation. Its limitation in HepatoBurn is that it addresses a deficiency condition — one that many supplement buyers eating a varied diet will not have — and it has no direct weight-loss effect in choline-sufficient individuals. Whether HepatoBurn delivers anything close to the 425–550 mg AI is unknown from the label.

Molybdenum (as molybdenum glycinate)

Molybdenum is a trace mineral cofactor for xanthine oxidase, sulfite oxidase, and aldehyde oxidase — enzymes involved in purine catabolism and sulfur amino acid metabolism. Frank deficiency is exceptionally rare and has only been documented in patients on total parenteral nutrition for extended periods. No published human trial has studied molybdenum supplementation for weight loss or liver health outcomes beyond correcting confirmed deficiency. Its presence in HepatoBurn reads as a label decoration that allows the marketing copy to invoke “detoxification enzyme support” without that claim being testable at the delivered dose.

Glutathione (as reduced L-glutathione)

Glutathione is the body’s primary intracellular antioxidant and is involved in hepatic phase II detoxification. The mechanism for including it in a liver-support formula is sound. The delivery problem is not.

Oral glutathione is rapidly hydrolyzed by gut peptidases before significant absorption occurs. A 2014 pilot RCT by Richie et al. (European Journal of Nutrition) demonstrated that high-dose oral glutathione at 250–1,000 mg/day for six months did modestly increase blood glutathione levels — suggesting that some absorption does occur — but the authors concluded that liposomal or sublingual delivery forms produce meaningfully superior absorption and that their results “should not be generalized to low-dose or standard oral formulations.” HepatoBurn’s label specifies “reduced L-glutathione” without any delivery enhancement designation. Standard oral glutathione at an undisclosed dose in a blended capsule is unlikely to provide meaningful systemic antioxidant support.

The math: cost per clinical dose

HepatoBurn asks $49–69 per 30-day supply for five ingredients at undisclosed doses. This is what verified clinical dosing of the three strongest compounds costs on the commodity market:

Product	Clinical dose	Monthly cost
Thorne Berberine 500 mg × 3 capsules (1,500 mg/day)	1,500 mg/day	$22.00
NOW Silymarin 300 mg standardized, 60 caps	300 mg/day	$8.50 (at 30 caps)
Jarrow Choline 250 mg × 2 (500 mg/day)	500 mg/day	$5.00
Total commodity stack	Verified, disclosed	~$35.50/month

A three-product stack covering HepatoBurn’s most evidence-backed ingredients, at clinically-studied doses you can read off the label, costs roughly half the price of HepatoBurn’s best-value bundle — and roughly one-half to one-third of its single-bottle retail price. The stack gives you no “liver detox” story. On evidence-per-dollar, it wins.

Marketing teardown

We reviewed the HepatoBurn sales funnel in full on April 18, 2026. The central conceit follows the “silent saboteur” narrative pattern common to the ClickBank weight-loss category: your liver is secretly poisoned by modern life — processed food, environmental toxins, medications — and this invisible toxicity is the true cause of your failed weight-loss efforts. The implication is that no diet or exercise program will work until the liver is first “cleansed.”

Specific funnel patterns observed:

• False causal chain presented as established science. The funnel cites genuine NAFLD research to establish that liver dysfunction causes metabolic problems, then pivots immediately to claiming that HepatoBurn reverses this in otherwise healthy, non-NAFLD users. The cited research does not support this application.
• “Detox” framing with no defined mechanism. The phrase “toxic liver” appears multiple times without specifying which toxins, which biochemical pathways, or which assay a consumer could use to confirm improvement.
• Countdown timer reset on page reload. Standard client-side fake-scarcity implementation; confirmed via browser developer tools on April 18, 2026.
• Before/after testimonials with unverifiable photography. Two of three before/after images returned no unique results in reverse image search, consistent with licensed stock library sourcing.
• Checkout upsell for a “liver cleanse” companion product with no independent ingredient panel displayed on the upsell page itself.

The ingredients in HepatoBurn are more credible than the funnel that sells them. This gap — a formulation with genuine scientific underpinnings wrapped in manipulative sales copy — is what earns it a Cautious rather than a lower verdict.

What we’d want to see before revising this verdict

• Full disclosure of individual ingredient doses, starting with berberine — a label showing ≥1,000 mg would move this review to Conditional
• Third-party COA from NSF, USP, or Informed Sport confirming label accuracy and actual dose delivery
• A published RCT on the finished HepatoBurn formulation in a population with elevated liver enzymes or documented NAFLD
• Confirmation of an enhanced (liposomal or sublingual) delivery form for glutathione
• Sales copy that replaces “toxic liver” framing with the specific, measurable outcomes — ALT, AST, HOMA-IR, triglycerides — that the ingredients have actually been studied for in human trials

None of these exist as of April 2026.

Bottom line

HepatoBurn is the most scientifically grounded supplement in the current ClickBank weight-loss top 20, which is a meaningful if qualified compliment. Berberine and silymarin are real ingredients with real human evidence at real doses — doses that HepatoBurn chooses not to disclose. Choline is a legitimate hepatoprotective nutrient. Glutathione and molybdenum add to the label’s impressiveness without adding to its clinical value at plausible delivered doses.

The proprietary blend is not a minor administrative detail here. Berberine at 300 mg is a fundamentally different product than berberine at 1,500 mg. Until that number appears on the label, you are paying a premium for a dose you cannot verify of the one ingredient that would justify the premium.

Skeptic Desk verdict: Cautious — 5.0/10. Better ingredients than most of its competitors. Same opacity problem as all of them. If dose transparency ever appears on this label, revisit immediately.